

Cyber Essentials Plus Assessment Report

Assessment of:	Roche Diabetes Care Limited
Assessed by (Certification Body)	Hytec
Assessed by (Assessor name)	Colin Chambers
Assessed by (Lead Assessor name)	Colin Chambers
Date of assessment visit	1st March 2021
Date of report:	2021-03-15

Cyber Essentials Plus certification can only be issued by a licensed Certification Body.

You can confirm the authenticity of this report by contacting IASME Consortium

+44 (0)3300 882752



1. About this report

Cyber Essentials Plus is the audited version of the Cyber Essentials information security standard. Cyber Essentials requires organisations to have a number of technical and procedural controls in place to improve their information security in order to mitigate common internet-borne cyber attacks. Cyber Essentials Plus is a series of tests that provide a further level of assurance that these technical controls have been successfully implemented within an organisation.

This report is a record of the Cyber Essentials Plus audit of Roche Diabetes Care Limited against the Cyber Essentials standard that has been carried out by Colin Chambers of the Certifying Body Hytec.

Cyber Essentials provides assurance that a number of key information security controls are in place within an organisation. For further assurance, the IASME information security standard provides a broader set of controls that enable good information security governance across an organisation.

1.1. Summary of findings

The authenticated internal scan did disclose some vulnerabilities that are not a fail but recorded in a recommendation report to the organisation.

The assessor has concluded that Roche Diabetes Care Limited has passed the required tests and should be awarded the Cyber Essentials Plus certification.

If a test has not been passed successfully, the assessor has provided feedback within the relevant section.

1.2. Evidence of activities

In carrying out the audit, the assessor will have carried out a number of technical tests and have seen documentary evidence. This evidence forms the basis for the assessor's recommendations and where appropriate has been included in this report.

2. Scope

N3/HSCN connection 10.197.170.0/25
Internet connectivity 198.21.21.0/24
198.21.20.0/23
194.120.84.0/23
196.3.37.0/24
196.3.38.0/24
196.3.48.0/21
72.34.128.0/19
196.3.54.212
196.3.56.0/24
198.21.16.0/24
198.21.31.0/24
206.53.226.0/23
211.144.221.0/27

Burgess Hill Office LAN 10.130.61.0/23

Certain items will be out of scope for the Cyber Essentials Plus assessment. Notable exceptions are listed below:

NHS N3/HSCN Routers/Managed by third party and in front of a firewall

3. External Testing

3.1. Test 1 – Remote vulnerability assessment

This test was awarded **PASS** by the assessor.

The test did not identify any vulnerabilities that were scored 7 or higher on CVSS v3 during the testing of the external IP addresses.

4. Internal testing

A suitable sample set of devices was selected as follows:

5x Laptops Windows 10 Build 1909 (over 61 in use)

5x Iphone/Ipad IOS 14.x (over 61 in use)

4.1. Test 2 – Review of device patching

This test was awarded **PASS** by the assessor.

No vulnerabilities were identified for the tested devices that were scored 7 or higher on CVSS v3 and that met the parameters listed in the Cyber Essentials Plus guidance.

4.2. Test 3 – Review of malware protection

This test was awarded **PASS** by the assessor.

It was identified that Roche Diabetes Care Limited is using the following methods of malware protection in their organisation:

- A - Anti-malware software
- B - Limiting installation of applications to an approved set

A - Anti-malware software

Anti-malware software is correctly installed and configured on all devices that rely on this method

B - Limiting installation of applications to an approved set

This method of anti-malware protection is correctly configured on all devices that rely on it.

4.3. Test 4 – Review of protection against malware sent by email

This test was awarded **PASS** by the assessor.

The standard set of test files was sent to each End User Device in the sample set via email.

All of the malware test files were successfully blocked by the End User Devices.

All of the non-malware test files prompted a suitable warning or opportunity to cancel before opening for all End User Devices.

4.4. Test 5 – Review of protection against malware delivered through a website

This test was awarded **PASS** by the assessor.

The standard set of test files was attempted to be accessed via a website on all End User Devices within the sample set.

All of the malware test files were successfully blocked by the End User Devices.

All of the non-malware test files prompted a suitable warning or opportunity to cancel before opening for all End User Devices.



CERTIFICATE OF ASSURANCE

Roche Diabetes Care Limited

Charles Avenue, Burgess Hill, W Sussex, RH15 9RY

COMPLIES WITH THE REQUIREMENTS OF THE CYBER ESSENTIALS PLUS SCHEME

NAME OF ASSESSOR : Colin Chambers

CERTIFICATE NUMBER : IASME-CEP-003009

PROFILE VERSION : April 2020

SCOPE : Whole Company

DATE OF CERTIFICATION : 2021-03-15

RECERTIFICATION DUE : 2022-03-15

CERTIFICATION MARK



CERTIFICATION BODY



CYBER ESSENTIALS PARTNER



IASME
CONSORTIUM